NCT00185328View on ClinicalTrials.gov

Efficacy and Tolerability of Angeliq in Thai Women

PHASE4CompletedINTERVENTIONAL

Enrollment

55

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

December 31, 2006

Conditions

Postmenopause

Interventions

DRUG

Estradiol/DRSP (Angeliq, BAY86-4891)

1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY